We serve Chemical Name:5-bromo-2-(4-methylpiperazin-1-yl)-4-phenylmethoxypyrimidine CAS:885952-24-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-bromo-2-(4-methylpiperazin-1-yl)-4-phenylmethoxypyrimidine
CAS.NO:885952-24-9
Synonyms:4-BENZYLOXY-5-BROMO-2-(4-METHYL-1-PIPERAZINO)PYRIMIDINE;Pyrimidine,5-bromo-2-(4-methyl-1-piperazinyl)-4-(phenylmethoxy);MFCD06798241;4-(BENZYLOXY)-5-BROMO-2-(4-METHYLPIPERAZIN-1-YL)PYRIMIDINE
Molecular Formula:C16H19BrN4O
Molecular Weight:363.25200
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:494.3ºC at 760 mmHg
Density:1.396g/cm3
Index of Refraction:1.606
PSA:41.49000
Exact Mass:362.07400
LogP:2.57280
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-BENZYLOXY-5-BROMO-2-(4-METHYL-1-PIPERAZINO)PYRIMIDINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(BENZYLOXY)-5-BROMO-2-(4-METHYLPIPERAZIN-1-YL)PYRIMIDINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrimidine,5-bromo-2-(4-methyl-1-piperazinyl)-4-(phenylmethoxy) Use and application,MFCD06798241 technical grade,usp/ep/jp grade.
Related News: “In the past few years, the pharmaceutical industry has seen rapid growth driven by the growth of small molecules’ innovations, complex APIs and the increasing need to optimize available resources. N-(2,2-Dichloro-1-methyl-vinyl)-benzamide manufacturers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. sodium 2-(4-(benzylthio)phenyl)-6-fluoro-3-methylquinoline-4-carboxylate suppliers This commercial API license is incredibly important as it marks the next phase in our growth and enables us to support customers from concept to commercialization. We are now able to fill the gap in the market for small-scale commercial API requirements while maintaining our expertise in delivering early-stage programs.” [5-(4-Dimethylamino-phenyl)-3,7-diphenyl-[1,2]diazepin-1-yl]-phenyl-methanone vendor & factory Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.”,It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time.
